Table 2.
Medication of the study population including 67 patients with NOD2 variants
| Medication | Study collectivea | WT NOD2 statusb | NOD2 carrierc |
|---|---|---|---|
| Budesonide | 50.8% (94/185) | 44.1% (52/118) | 62% (42/67) |
| Prednisolone | 75.7% (140/185) | 66.1% (78/118) | 92.5% (62/67) |
| Immunomodulators | 36.7% (68/185) | 39.7% (35/118) | 49.2% (33/67) |
| Anti-TNF-α | 13.5% (25/185) | 15.3% (18/118) | 10.4% (7/67) |
aPercentage of patients of the total study collective receiving the indicated medication. The numbers in parentheses indicate the total numbers of patients within the study collective of 185 patients treated by the indicated medication
bPercentage of patients with the WT NOD2 status treated by the indicated medication. The numbers in parentheses indicate the total numbers of 118 patients with WT NOD2 status receiving the indicated medication
cPercentage of patients with NOD2 variants receiving the indicated medication. The numbers in parentheses indicate the total numbers of 67 patients with NOD2 variants treated by the indicated medication